Well, the Olympics are now over, so it's back to looking for GOLD in the stock market, Surprisingly, we have no GOLD stocks in our Rocket list this week.
Remity Global Inc. RELY
What's depressing? Wiping out in speed skating and losing a gold medal in the Olympics. What's MORE depressing? Being the CEO of a company, then resigning, and then seeing your company stock soar. That's the story on Remity this week, whose CEO Matt Oppenheimer stepped down from the company after leading it for 15 years. RELY stock soared 35% last week on the news. Sure, it didn't hurt that the money-transmission company reported strong financial results, and the incoming CEO has a solid background. But still, that's gotta hurt one's ego.
Remity Global Inc. RELY
What's depressing? Wiping out in speed skating and losing a gold medal in the Olympics. What's MORE depressing? Being the CEO of a company, then resigning, and then seeing your company stock soar. That's the story on Remity this week, whose CEO Matt Oppenheimer stepped down from the company after leading it for 15 years. RELY stock soared 35% last week on the news. Sure, it didn't hurt that the money-transmission company reported strong financial results, and the incoming CEO has a solid background. But still, that's gotta hurt one's ego. 
ImmunityBio Inc. IBRX Immunity shares gained 46% last week as its new bladder cancer drug got European approval. It's a good news story all around, as shares in the company are now up 340% for the year so far. The company is still losing money, but with approvals sales are expected to more than double this year. We don't often joke about cancer companies, except for the Dud below, but patients and shareholders are still no doubt smiling.
Immunity shares gained 46% last week as its new bladder cancer drug got European approval. It's a good news story all around, as shares in the company are now up 340% for the year so far. The company is still losing money, but with approvals sales are expected to more than double this year. We don't often joke about cancer companies, except for the Dud below, but patients and shareholders are still no doubt smiling. 
GRAIL Inc. GRAL 
This one should have been easy. Investors for centuries have been looking for the Holy Grail in the stock market. Searching stock listings, it should have been obvious that a stock named Grail was going to be a winner. But the stock market is a cruel mistress. GRAL shares plunged 49% last week on news that its cancer detection test failed to meet its clinical goals. So, Grail shares collapsed: Insert Monty Python joke here.
This one should have been easy. Investors for centuries have been looking for the Holy Grail in the stock market. Searching stock listings, it should have been obvious that a stock named Grail was going to be a winner. But the stock market is a cruel mistress. GRAL shares plunged 49% last week on news that its cancer detection test failed to meet its clinical goals. So, Grail shares collapsed: Insert Monty Python joke here. 
JFrog Ltd. FROG FROG shares fell 27% last week. Just another victim in the 2026 software destruction caused by AI. Cybersecurity companies such as JFrog were supposed to see increased business from AI, but when Antrhopic released 'Claude Code Security' last week the whole sector plunged. The AI-agent scans software codebases for security vulnerabilities that traditional methods often miss. Translated: Companies might not need as much cyber protection from third-party companies anymore. We can't predict how this will all turn out, but we still have some suggestions to help JFrog: MAYBE DON'T NAME YOUR COMPANY "FROG".
FROG shares fell 27% last week. Just another victim in the 2026 software destruction caused by AI. Cybersecurity companies such as JFrog were supposed to see increased business from AI, but when Antrhopic released 'Claude Code Security' last week the whole sector plunged. The AI-agent scans software codebases for security vulnerabilities that traditional methods often miss. Translated: Companies might not need as much cyber protection from third-party companies anymore. We can't predict how this will all turn out, but we still have some suggestions to help JFrog: MAYBE DON'T NAME YOUR COMPANY "FROG".
Klarna Group PLC. KLAR Giving out loans to sub-prime and distressed consumers, who can't afford to pay $499 for a new TV. What could possibly go wrong? Well, Klarna investors found out last week. KLAR shares, which went public with a big bang less than six months ago at $40 a share, dropped 28% last week to $13, after the company reported a 59% increase in loan loss provisions. Sure, quarterly revenue rose more than 38% to $1 billion, but that means little with a $250 million loan loss provision. Buy-now-pay-later? For stock holders, it has been more like Buy-now-lose-money. Ouch.
Giving out loans to sub-prime and distressed consumers, who can't afford to pay $499 for a new TV. What could possibly go wrong? Well, Klarna investors found out last week. KLAR shares, which went public with a big bang less than six months ago at $40 a share, dropped 28% last week to $13, after the company reported a 59% increase in loan loss provisions. Sure, quarterly revenue rose more than 38% to $1 billion, but that means little with a $250 million loan loss provision. Buy-now-pay-later? For stock holders, it has been more like Buy-now-lose-money. Ouch. 
Take Care,
Unlock the Power of Informed Investing with 5i Research!
DIY investing doesn't have to mean going it alone. At 5i Research, we're your trusted partner in navigating the stock market. Our platform offers comprehensive stock and market research, empowering you to make smart investment decisions.
- Investor Q&A: Have burning questions? Get answers from our team of experts and fellow investors in our dedicated Q&A section.
- Research Reports: With over 60 meticulously researched Canadian stocks, our reports offer in-depth analysis, giving you the confidence to invest wisely.
- Model Portfolios, Alerts, Forums, Portfolio Tracking, and Much More..
Analysts of 5i Research responsible for this report do not have a financial or other interest in securities mentioned. The i2i Fund does not have a financial or other interest in securities mentioned.
Comments
Login to post a comment.